Dr. David Stamler

Dr. David Stamler is the Chief Executive Officer at Alterity Therapeutics, where his extensive career in clinical development and leadership has significantly shaped the company's mission to develop disease-modifying treatments for neurodegenerative disorders. His tenure at ATHE began in May 2017 when he joined as Chief Medical Officer and Senior Vice President, Clinical Development, and he was subsequently promoted to CEO in January 2021, marking a period of strategic growth and strengthened clinical focus.

Before joining ATHE, he held key leadership positions at several reputed biopharmaceutical companies. His roles have included serving as Vice President, Clinical Development and Therapeutic Head for Movement Disorders at Teva Pharmaceutical Industries following Teva’s acquisition of Auspex Pharmaceuticals, as well as Chief Medical Officer positions at Auspex Pharmaceuticals and XenoPort, Inc. This diverse background in clinical research and drug development has provided him with a broad and in-depth understanding of the pharmaceutical industry.

Throughout his career, Dr. Stamler has contributed to the advancement of novel drug candidates and clinical studies, demonstrating a strong commitment to improving patient outcomes. His work on projects such as ATH434 at ATHE and his involvement with other therapies at previous companies highlight his role in driving forward innovative treatment approaches for complex neurological conditions.

An alumnus of the University of Chicago, his academic background in medicine and biology forms the foundation for his clinical expertise and leadership abilities. His journey from various leadership roles in established pharmaceutical companies to his current executive position at ATHE underscores both his experience and dedication to the field of medical science and patient care.